Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoint_Dr.Jing_Watnick_&_Dr. Lou_Vaickus_2021
PharmaShots Interview: Vigeo Therapeutics’ Dr. Lou Vaickus and Dr. Jing Watnick Share Insights on VT1021 Data Presented at SITC 2020
In a recent interview with PharmaShots, Dr. Jing Watnick, Co-Founder and Chief Executive Officer, and Dr. Lou Vaickus, Interim Chief Medical Officer at Vigeo shared their views on the data findings presented at the SITC 2020 Annual Meeting that demonstrated VT1021 as a single-agent has a favorable safety profile and shows early signals of clinical activity across a wide variety of…
January 15, 2021
Viewpoint_Kiran_Patel_2021
PharmaShots Interview: Janssen’s Kiran Patel Shares Insights on Amivantamab for Metastatic EGFR Exon 20+ NSCLC
In a recent interview with PharmaShots, Kiran Patel, Vice President Clinical Development, Solid Tumor Franchise at Janssen shared his views on the regulatory submission of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Shots: Janssen reported the BLA submission to the US FDA seeking approval of Amivantamab for the…
January 13, 2021
Viewpoint_Andrew_Greenspan_2021
PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020
In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen's commitment to advance research in rheumatic disease. Shots: Janssen presented clinical trial results in 35 abstracts featuring findings across PsA, RA, and SLE at ACR Convergence 2020 Virtual Scientific Program Sixteen abstracts focus on Tremfya in adults…
January 11, 2021
Viewpoint_Dr. Riju_Ray_2021
PharmaShots Interview: GSK’s Dr. Riju Ray Shares Insights on the Role of Community-Based Pulmonologists in Improving COPD Management Among PCPs
In a recent interview with PharmaShots, Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading US medical affairs across asthma and COPD shared his views on how community-based pulmonologists are improving COPD management and education among referring PCPs. Shots: Pulmonologists identified 12 strong to moderate predictors of future COPD exacerbations, some of which were evaluated…
January 7, 2021
Viewpoint_Kimberly_Smith_2020
PharmaShots Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data of Long-Acting Cabotegravir and Rilpivirine Presented at IDWeek 2020
In a recent interview with PharmaShots, Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare shared information on the positive findings presented at the 2020 Infectious Diseases Society of America (IDWeek) and the impact of COVID-19 on the development of long-acting cabotegravir and rilpivirine. Shots: The company reported the positive findings of a pooled…
December 28, 2020
PharmaShots Interview: Neoleukin’s Daniel-Adriano Silva Shares Insight on Novel Protein Designed to Treat or Block SARS-COV-2
In a recent interview with PharmaShots Daniel-Adriano Silva, PhD, Co-founder and Vice President Head of Research at Neoleukin shared the significance and promise of the findings published in Science and discuss the details of its De Novo Protein Design Shots: NL-CVX1 (CTC-445.2d) demonstrated the ability to prevent infection of multiple human cell lines in vitro and to protect…
December 18, 2020
Viewpoint_Noreen_Heng_2020
PharmaShots Interview: Kezar’s Noreen Henig Shares Insight on Therapeutic Potential of KZR-616
In a recent interview with PharmaShots, Noreen Henig, Chief Medical Officer at Kezar Life Sciences shared information on clinical and pre-clinical data supporting the potential of KZR-616 to positively affect multiple drivers of immune-mediated diseases. Shots: The poster presented at ACR 2020 includes additional patient-weeks of safety and tolerability data compared to prior data presentations for our…
December 17, 2020
ViewPoint_William_F_Doyle_2020
PharmaShots Interview: Novocure’s William F. Doyle Shares Insight on Company’s Accomplishments in the Treatment of Glioblastoma and Mesothelioma
In a recent interview with PharmaShots, William F. Doyle, Executive Chairman at Novocure shared information about the company's activities in the field of glioblastoma and mesothelioma. He also discussed the company's technology, Tumor Treating Fields (TTFields), and its potential for broad applicability across solid tumors. Shots: Novocure is a global oncology company working to extend survival…
December 9, 2020
Load more